Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-28
2009-06-09
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S277000, C564S321000, C564S503000
Reexamination Certificate
active
07544689
ABSTRACT:
The present invention relates to compounds of formula Ior pharmaceutically acceptable salts thereof, whereinone of R1and R2is methyl, ethyl or isopropyl, and the other is H;R3and R4are each independently H, branched or un branched C1-C6alkyl, or aryl, and wherein at least one of R3and R4is other than H;R5is a branched or unbranched C1-C5alkyl group or a C1-C6cycloalkyl group, each of which may be optionally substituted with one or more OH groups;R6, R7, R8and R9are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2.A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.
REFERENCES:
patent: 2164271 (1939-06-01), Hass et al.
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 6110923 (2000-08-01), Ely et al.
patent: 6255485 (2001-07-01), Gray et al.
patent: 6316456 (2001-11-01), Meijer et al.
patent: 6531479 (2003-03-01), Wang et al.
patent: 6552192 (2003-04-01), Hanus et al.
patent: 6573044 (2003-06-01), Gray et al.
patent: 6627633 (2003-09-01), Trova
patent: 6699854 (2004-03-01), Wang et al.
patent: 6790958 (2004-09-01), Lum et al.
patent: 6949644 (2005-09-01), Ding et al.
patent: 7262202 (2007-08-01), Fischer et al.
patent: 7388015 (2008-06-01), Wang et al.
patent: 2002/0049218 (2002-04-01), Meijer et al.
patent: 2003/0087906 (2003-05-01), Trova
patent: 2003/0092909 (2003-05-01), Trova
patent: 2003/0191312 (2003-10-01), Ding et al.
patent: 2003/0229105 (2003-12-01), Kashanchi
patent: 2005/0009846 (2005-01-01), Fischer et al.
patent: 2005/0192300 (2005-09-01), Wang et al.
patent: 2005/0256142 (2005-11-01), Fischer et al.
patent: 2005/0282843 (2005-12-01), Wang et al.
patent: 2005/0288307 (2005-12-01), Wang et al.
patent: 2006/0040997 (2006-02-01), McInnes et al.
patent: 2006/0183760 (2006-08-01), Fischer et al.
patent: 2006/0199830 (2006-09-01), Wang et al.
patent: 2006/0241297 (2006-10-01), Wang et al.
patent: 2006/0264628 (2006-11-01), McInnes et al.
patent: 2007/0021419 (2007-01-01), Wang et al.
patent: 2007/0021452 (2007-01-01), Wang et al.
patent: 2007/0185134 (2007-08-01), Fischer et al.
patent: 2008/0125404 (2008-05-01), Benigni et al.
patent: 2008/0176858 (2008-07-01), Beauglehole et al.
patent: 270828 (1950-09-01), None
patent: 0665229 (1995-08-01), None
patent: 7-75798 (1995-03-01), None
patent: WO-90/09178 (1990-08-01), None
patent: WO-93/17020 (1993-09-01), None
patent: WO-97/16452 (1997-05-01), None
patent: WO-97/20842 (1997-06-01), None
patent: WO-98/05335 (1998-02-01), None
patent: WO-98/16528 (1998-04-01), None
patent: WO-99/07705 (1999-02-01), None
patent: WO-99/34018 (1999-07-01), None
patent: WO-99/43676 (1999-09-01), None
patent: WO-00/44750 (2000-08-01), None
patent: WO-00/55161 (2000-09-01), None
patent: WO-03/057218 (2003-07-01), None
Abraham, RT et al., “Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases,”Biol. Cell., vol. 83:105-120 (1995).
Chang, Young-Tae et al., “Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors,”Chemistry&Biology, vol. 6:361-375 (1999).
De Azevedo, Walter Filgueira et al., “Inhibition of cyclin-dependent kinases by purine analogues, Crystal structure of human cdk2 complexed with roscovitine,”Eur. J. Biochem., vol. 243:518-526 (1997).
Diwan, Prerna et al., “Roscovitine Inhibits Activation of Promoters in Herpes Simplex Virus Type 1 Genomes Independently of Promoter-Specific Factors,”Journal of Virology, vol. 78(17):9352-9365 (2004).
Ducrot, Pierre et al., “3D-QSAR CoMFA on Cyclin-Dependent Kinase Inhibitors,”J. Med. Chem., vol. 43:4098-4108 (2000).
Fukatsu, Shunzo et al., “Synthesis of “Reversed” Nucleosides of Some Purine and Pyrimidine Bases,”Bulletin of the Chemical Society of Japan, vol. 46:3165-3168 (1973).
Giocanti, Nicole et al., “In Vitro Evaluation of a Novel 2,6,9-Trisubstituted Purine Acting As a Cyclin-Dependent Kinase Inhibitor,” retrieved online at http://www.annalsnyas.org/cgi/content/citation/886/1/180 (1999).
Gray, Nathanael et al., “ATP-site Directed Inhibitors of Cyclin-dependent Kinases,”Current Medical Chemistry, vol. 6:859-875 (1999).
Gray, Nathanael S. et al., “Exploiting Chemical Libraries, Structure, and Genomics in the Search for Kinase Inhibitors,”Science, vol. 281:533-538 (1998).
Havli{hacek over (c)}ek, Libor et al., “Cytokinin-Derived Cyclin-Dependent Kinase Inhibitors: Synthesis and cdc2 Inhibitory Activity of Olomoucine and Related Compounds,”J. Med. Chem., vol. 40:408-412 (1997).
Holy, Antonin, “Syntheses of Enantiomeric N-(3-Hydroxy-2-Phosphono-Methoxypropyl) Derivatives of Purine and Pyrmidine Bases,” Collect. Czech. Chem. Commun., vol. 58:649-674 (1993).
Imbach, Patricia et al., “2,6,9-Trisubstituted Purines: Optimization Towards Highly Potent and Selective CDK1 Inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 9:91-96 (1999).
Legraverend, Michel et al., “Synthesis and In Vitro Evaluation of Novel 2,6,9-Trisubstituted Purines Acting as Cyclin-dependent Kinase Inhibitors,” Bioorganic & Medicinal Chemistry, vol. 7:1281-1293 (1999).
Meijer, Laurent et al., “Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of cyclin-dependent kianses cdc2, cdk2 and cdk5,” Eur. J. Biochem., vol. 243:527-536 (1997).
Oh, Chang-Hyun et al., “Synthesis and Biological Activities of C-2, N-9 Substituted 6-Benzylaminopurine Derivatives as Cyclin-Dependent Kinase Inhibitor,” Arch. Pharm. Pharm. Med. Chem., vol. 332:187-190 (1999).
Rudolph, Bettina et al., “Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but no apoptosis,” The EMBO Journal, vol. 15(12):3065-3076 (1996).
Schow, Steven R. et al., “Synthesis and Activity of 2,6,9-Trisubstituted Purines,” Bioorganic & Medicinal Chemistry, vol. 7(21):2697-2702 (1997).
Sielecki, Thais M. et al., “Dyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation,” Journal of Medicinal Chemistry, vol. 43(1):1-18 (2000).
Tao, G.-Q. et al., “Inhibitors of Cytokinin Metabolism III. The Inhibition of Cytokinin N-Glucosylation in Radish Cotyledons,” Journal of Plant Growth Regulation, vol. 10:179-185 (1991).
Veeranna, K.T. et al., “Inhibition of Neuronal Cyclin-Dependent Kinase-5 by Staurosporine and Purine Analogs Is Independent of Activation by Munc-18,” Neurochemical Research, vol. 21(5):629-636 (1996).
Veselý, Jaroslav et al., “Inhibition of cyclin-dependent kinases by purine analogues,” Eur. J. Biochem., vol. 224:771-786 (1994).
International Search Report for Application No. PCT/GB03/03544, dated Feb. 19, 2004.
Fischer Peter Martin
Jarman Michael
McDonald Edward
Nutley Bernard
Raynaud Florence
Berch Mark L
Cancer Research Technology Limited
Cyclacel Limited
Kanik Cynthia L.
Lahive & Cockfield LLP
LandOfFree
Purine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4072000